Understanding how PD-L1 affects immune responses in breast cancer
PD-L1 Intracellular RNA binding function regulates immune suppression
This study is looking at how a protein called PD-L1 helps triple negative breast cancer hide from the immune system, and it aims to find new ways to improve treatments by understanding how this protein affects immune responses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10906918 on NIH RePORTER |
What this research studies
This research investigates the role of PD-L1, a protein that helps tumors evade the immune system, particularly in triple negative breast cancer (TNBC). The study focuses on how intracellular PD-L1 functions as an RNA binding protein, influencing the stability of certain RNAs that affect immune responses. By examining the interactions between PD-L1 and regulatory T cells, the research aims to uncover new mechanisms of immune suppression and therapeutic resistance in cancer. Patients may benefit from insights that could lead to improved treatments targeting these pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer.
Not a fit: Patients with other types of breast cancer or those not expressing PD-L1 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance anti-tumor immunity in breast cancer patients.
How similar studies have performed: Previous research has shown promising results in targeting PD-L1 pathways, indicating potential for success in this novel approach.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Mutter, Robert W — Mayo Clinic Rochester
- Study coordinator: Mutter, Robert W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.